Navigation Links
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Date:8/19/2007

MISSISSAUGA, ON, Aug. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announces that the information required to be disclosed in accordance with Rule 26 of the AIM Rules for Companies is available in the "Shareholder Information/Rule 26 Disclosures" section on the Company's home page, http://www.ymbiosciences.com.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) for which recruitment in a Phase III trial in pediatric glioma has just been completed and which is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment o
'/>"/>

SOURCE YM BioSciences Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... Oct. 22, 2014 Research and Markets ... Market by Material, by Application, Geography - Global Analysis ... offering. Organic electronics, also called as ... material science which deals with small conductive molecules and ... small molecules and polymers are carbon based, made using ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Sidney Kimmel Cancer Center at Thomas Jefferson University ... , Through the Strategic Alliance Partnership program, the ... will collaborate to raise awareness of the Center’s ... and other projects. Clinicians and other health care ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... January 12 Bavarian Nordic,owns several United States ... core technology, MVA-BN(R), which is the basis for ... a vector for delivering,recombinant vaccines. Bavarian Nordic has ... infringement action. The claim in this case is ...
... ALAMEDA, Calif., Jan. 12 Singulex, Inc. today announced ... led by JAFCO Co., Ltd. and supported by existing ... round will support the commercialization of Singulex technologies in ... Hozoji, investment officer for JAFCO Life Science Investment, will ...
... Pharmaceuticals today,announced that it has achieved its first candidate ... GlaxoSmithKline. Anacor may,receive future milestone payments and royalties ... sales. , "We are pleased ... result of,the alliance we have built between our team ...
Cached Biology Technology:Bavarian Nordic's Case Against Oxford BioMedica 2Singulex Closes $19 Million Financing Round 2Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate 2
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... Ebola is critical and pertinent for practicing physicians and ... and epidemic. The Journal, Disaster Medicine and Public ... Virus and Public Health, to surround the public, medical ... societal moment. , On October 17, the journal ... The primer was prepared by Dr. Eric Toner, internist ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... , April 17, 2013 Vermillion, Inc. (NASDAQ: ... on gynecologic cancers and women,s health, announced the signing of ... U.S. Army Medical Research and Materiel Command (USAMRMC). ... Reduction Using OVA1 in a Treatment Algorithm for Adnexal ...
... 100% biodiesel (B100) "blend stock" samples by the U.S. ... that 95% of the samples from 2011-12 met ASTM ... guidelines for industry and are designed to ensure quality ... operation of the nation,s vehicles powered by biodiesel blends. ...
... 16, 2013 - BGI Health and ACIBADEM Healthcare ... Company Molecular Biology, signed a Memorandum of Understanding ... technologies to Turkey and improving Turkish reproductive healthcare. ... testing technologies in the areas of Monogenic disorders, ...
Cached Biology News:U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 2U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 3U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 4NREL survey shows dramatic improvement in B100 biodiesel quality 2BGI Health forms partnership with ACIBADEM hospital on genetic disease testing 2